After recording a new 52-week high of $0.47 on last Thursday, the stock price of Decision Diagnostics Corp (OTCMKTS:DECN) eroded a part of its gains and closed the week at $0.395. The decline came at a share volume of 290,868 compared to average share volume of 354,825. The initial gains can be attributed to a yet another positive announcement that the company made last week.
Excitingly enough, this time Decision Diagnostics didn’t report a lawsuit, as it most often does. The company gave investors some positive news as it approached closer towards a board representation deal with Retail Monster LLC. Investors got thrilled after the issue of news, and it was quite evident as Decision Diagnostics can draw incredible benefits from such a contract.
As per the last financial report, Decision Diagnostics has cash of $627,000. The total current assets amounted to $2.3 million while current liabilities came at $1.8 million. However, the revenue in the reported period came at $514,000 while net operating loss was $2.4 million.
Analyzing the numbers, it is evident that the figures are not the worst numbers that one could list on the OTC Markets platform by a long shot. But it is also true that such figures don’t really boost investor confidence, either. What is even more disheartening for investors is the fact that as per the latest update, 2000 shares of the Decision Diagnostics’ Series “B” Preferred Stock were released and outstanding as of end of December 2015.
Each one of these shares can be converted into common stock at a price of one for $15,000. There are additional 687 million shares of the company’s series “E” stock, and each can be converted into 14 shares of its common stock. Almost, 100 million of these were released in last year, which is indicative of firm’s approach towards investor value.